Zacks Investment Research
10 Jul 2026, 15:41 UTC · 1h ago
Immunome Stock Up 32% in a Month: Here's What You Should Know
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Jul 2026, 15:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA has accepted Immunome's New Drug Application (NDA) for varegacestat to treat adults with desmoid tumors. — FDA acceptance is a critical regulatory milestone that moves a candidate drug closer to commercialization and revenue generation.
+0.60The phase III RINGSIDE study for varegacestat demonstrated an 84% reduction in the risk of disease progression or death compared to placebo. — Strong clinical efficacy data increases the probability of regulatory approval and future market adoption.
+0.50The FDA decision on varegacestat is expected on April 28, 2027. — Provides a specific long-term catalyst date, though the distant timeline limits immediate price volatility.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Immunome plans to submit a marketing authorization application for varegacestat to the European Medicines Agency by the end of 2026. — Indicates a strategy for geographic expansion and additional future revenue streams.
Which stocks this story touches
The FDA accepted the company's NDA for varegacestat and the stock has rallied significantly due to positive clinical progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
10h ago
